NCT00739973
Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Amlodipine in Essential Hypertension
See it on ClinicalTrials.gov ↗1,688 people
49.2%
50.8%
830 womenmiddle line = equal numbers858 men
- Phase
- PHASE3
- Paid for by
- Novartis Pharmaceuticals
- Finished
- 2009-05
- Health conditions
- Hypertension
- Who could join
- Anyone
- Ages
- 18 Years – no maximum
- Average age
- mean 54.1 years
- Age 65+
- Not reported
- Weight (BMI)
- Not reported
- Pregnancy recorded
- Not reported
- Menopause recorded
- Not reported
- Results shown by sex
- Not split by sex
- Race
- Not reported
Women left out
- No pregnant women
Women who were pregnant could not join.
“Pregnant or nursing (lactating) women”
- No breastfeeding moms
Women who were breastfeeding could not join.
“Pregnant or nursing (lactating) women”
- No women who could get pregnant
Most women roughly 15–50 years old were turned away.
“Women of child-bearing potential”
- No heart disease
Women with heart disease, heart rhythm problems or a past heart attack were turned away.
“Previous or current diagnosis of heart failure (NYHA Class II-IV).”
- No diabetes
Women with diabetes were turned away.
“Uncontrolled Type 1 or Type 2 diabetes mellitus”
- No cancer
Women with current or past cancer were turned away.
“History of malignancy within 5 years”
Study titles and rules are shown in their original English.